Nasdaq

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

Dogwood (DWTX) Therapeutics “announced top line data from the recently completed BHC IMC-2 Long-COVID study. The study was conducted via an investigator-initiated, investigational research grant ...
Seeking Alpha

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo ...
Nasdaq

Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2

(RTTNews) - Virios Therapeutics, Inc. (VIRI) announced receipt of the FDA feedback on requirements for advancing IMC-2, or a combination of valacyclovir + celecoxib, as a treatment for the fatigue, ...
Seeking Alpha

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (VIRI) (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to ...
Business Wire

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic ...
Business Wire

Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including ...